Education
About Us
Working with TipRanks
Follow Us
OrganoClick AB (SE:ORGC)
:ORGC
Top Page
OrganoClick AB
(Frankfurt:ORGC)
44Neutral
OrganoClick AB (ORGC) vs. S&P 500 (SPY)
Market Cap
kr215.86M
Dividend YieldN/A
Average Volume (3M)23.12K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue Growth-12.78%
EPS Growth-13.79%
CountrySE
Employees48
SectorBasic Materials
Sector Strength60
IndustryChemicals
Share Statistics
EPS (TTM)-0.18
Shares Outstanding98,117,966
10 Day Avg. Volume10,010
30 Day Avg. Volume23,121
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
OrganoClick AB Business Overview & Revenue Model
Company DescriptionOrganoClick AB (ORGC) is a Swedish company specializing in the development and production of environmentally friendly chemical products for various industries. It operates in sectors such as textiles, paper, and wood, providing innovative solutions like water-repellent and flame-resistant treatments. The company's core products leverage proprietary technology to offer sustainable alternatives to conventional chemical treatments, addressing the growing demand for eco-friendly industrial applications.
How the Company Makes MoneyOrganoClick AB generates revenue through the sale of its chemical products and treatments to industrial clients in the textiles, paper, and wood industries. The company's revenue model is based on direct sales and long-term supply agreements with businesses seeking sustainable alternatives to traditional chemical processes. Key revenue streams include licensing proprietary technology and selling treated materials that meet specific environmental standards. OrganoClick also benefits from partnerships with companies that prioritize sustainability, enabling it to expand its market reach and drive sales growth. Additionally, the company invests in research and development to continually enhance its product offerings and maintain a competitive edge in the green chemistry sector.
OrganoClick AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 127.23M | 145.87M | 115.05M | 110.06M | 96.46M | Gross Profit |
| 31.84M | 35.39M | 12.94M | 18.51M | 20.20M | EBIT |
| -9.86M | -9.23M | -40.95M | -27.90M | -17.25M | EBITDA |
| 5.71M | 5.95M | -21.19M | -12.92M | -4.41M | Net Income Common Stockholders |
| -17.97M | -15.77M | -41.62M | -31.03M | -19.52M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 538.00K | 10.74M | 15.20M | 34.25M | 32.03M | Total Assets |
| 126.98M | 150.75M | 162.86M | 188.39M | 152.80M | Total Debt |
| 50.56M | 62.39M | 60.68M | 53.54M | 43.36M | Net Debt |
| 50.02M | 51.65M | 45.47M | 19.29M | 11.33M | Total Liabilities |
| 89.15M | 97.34M | 95.30M | 80.66M | 69.86M | Stockholders Equity |
| 28.98M | 44.58M | 58.78M | 100.33M | 54.08M |
| Cash Flow | Free Cash Flow | |||
| -5.51M | -8.08M | -35.35M | -52.34M | -13.93M | Operating Cash Flow |
| 3.60M | 533.00K | -21.22M | -37.69M | 5.47M | Investing Cash Flow |
| -9.11M | -8.61M | -7.45M | -14.65M | -19.40M | Financing Cash Flow |
| -4.69M | 3.60M | 9.63M | 54.56M | -15.19M |
OrganoClick AB Technical Analysis
Negative
2.40
Price Trends
2.29
Negative
2.55
Negative
2.80
Negative
Market Momentum
<0.01
Negative
45.97
Neutral
40.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ORGC, the sentiment is Negative. The current price of 2.4 is above the 20-day moving average (MA) of 2.26, above the 50-day MA of 2.29, and below the 200-day MA of 2.80, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 45.97 is Neutral, neither overbought nor oversold. The STOCH value of 40.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ORGC.
OrganoClick AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €361.62M | 28.16 | -4.31% | ― | 35.99% | 95.51% | |
49 Neutral | $1.95B | -1.59 | -21.99% | 3.77% | 0.61% | -27.45% | |
48 Neutral | €204.98M | ― | -15.65% | ― | -10.46% | -680.00% | |
44 Neutral | kr215.86M | ― | -47.96% | ― | -12.78% | -13.79% | |
44 Neutral | €237.08M | ― | -5.94% | ― | 2.29% | 45.77% |
* Basic Materials Sector Average
Performance Comparison
SE:ORGC
OrganoClick AB
2.20
-0.85
-27.87%
SE:NEXAM
Nexam Chemical Holding AB
3.30
0.29
9.63%
SE:POLYG
Polygiene AB
9.90
0.40
4.21%
SE:SERT
Serstech AB
0.81
-0.42
-34.36%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.